The levels of glycated haemoglobin, fetal haemoglobin and methaemoglobin in 618 Saudi subjects were determined. A statistically significant decrease in the percentage of glycated haemoglobin was observed in all haemoglobinopathic groups studied in comparison to normal controls. However, there was no significant difference in the percentage of glycated haemoglobin in patients with sickle cell anaemia when compared with those sickle cell subjects who were also glucose-6-phosphate dehydrogenase deficient. This suggests that there is little survival advantage or disadvantage in the combination of glucose-6-phosphate dehydrogenase deficiency and sickle cell anaemia.
Both erythrocyte glucose-6-phosphate dehydrogenase (G6PD) deficiency and sickle cell anaemia (HbSS) are commonly found in the Eastern province of Saudi Arabia'< The interaction of these disorders has been of interest; different studies have suggested that G6PD deficiency has beneficial,' deleterious" or no influence" upon the course of HbSS. Previously it had been shown that Saudi sickle cell patients exhibited a benign clinical course compared to African sickle cell subjects." G6PD deficiency had been among other factors reported to modify the severity of sickle cell disease in the Saudi population."
Glycated haemoglobin (GHb) has been used as an index for the average survival time of red blood cells in sickle cell anaemia and in several other related Hb disorders." Recently the level of GHb was used as an index of the presumed ameliorating effects of G6PD deficiency upon sickle cell disease." However, the level of GHb in G6PD deficient patients was not reported. We were prompted therefore to investigate this hypothesis in Saudi subjects and to study this interaction in more detail.
Materials and methods
Blood samples were collected in EDTA tubes from patients aged between 13 and 35 years attending King Fahad Teaching Hospital and from volunteers attending the Blood Bank of the same hospital. Haematological indices (Hb, Correspondence: Dr A K Al-Ali. RBC, MCV, MCH) were determined for all samples using a haematology analyser (Cell Dyn 700; Sequoia-Turner, USA). Blood Iysates were prepared according to the method of Drabkin." Cellulose acetate Hb electrophoresis was performed on Helena electrophoresis system using Tris-EDTA borate buffer (pH 8 '6) . Colorimetric determination of methaemoglobin was carried out in whole blood within I h after venepuncture.'! Fetal haemoglobin (HbF) was quantified by the alkali denaturation method of Betke et al. l z GHb was estimated according to the modified thiobarbituric acid (TBA) method of McDonald et al."; 2 ml aliquots of the haemolysates (5% in haemoglobin) were incubated with I ml of 1·0 N oxalic acid for 4·5 h at lOO°e. After cooling to room temperature 1 ml of 40% trichloroacetic acid was added. Upon removal ofits precipitate, 2 ml of the resultant clear supernatant were mixed with a saturated solution of thiobarbituric acid. After mixing the solution was kept at 40°C for 30 min, after which it was cooled to room temperature. The reaction of 5-hydroxymethyl furfural with TBA gave a compound with an absorption maximum at 443 nm. The extinction coefficient of K("cm = 0·06 at 443 nm was used. G6PD activity was determined spectrophotometrically according to the method reported by Battistuzzi.l" Fasting blood glucose levels for all subjects were determined with a Du Pont automatic clinical analyser employing the hexokinase method. HbAz and reticulocyte count were determined to exclude the possibility ofactive haemolysis, or the 
Results
A total of6l8 blood samples were obtained from Saudi Arabian subjects of both sexes who met the criteria of being free of active haemolysis or fJthalassaemia trait. AIl subjects with G6PD activity less than 10 mU/10 9 erythrocytes were considered to be deficient. The mean level (± SD) of GHb in 67 G6PD deficient subjects was 6·04±0·47% and in a group of 100 sickle cell disease subjects was 4·4±0·8%. This value agrees with the previously reported level ofthis Hb in the Saudi sickle cell population." Both these values are statisticaIly different (P < 0'05) from that found in normal control subjects (Table I) . Moreover, the mean level (± SD) of GHb in the sickle cell trait group (HbAS) of 6·44 ± O' 7 was also determined. The mean level (± SD) of GHb in groups ofG6PD deficient with HbSS or HbAS subjects were 4·75±0·8% and 6·26±0·46%, respectively. The difference between the levels of GHb determined for subjects with HbSS and for subjects with both HbSS and G6PD deficiency was not statistically significant (P> 0,05). Table 2 shows the percentage of HbF and methaemoglobin found in each ofthe groups studied. The mean values of HbF concentration in HbSS Saudi patients with and wihout G6PD deficiency are very similar. These values are significantly different (P=O'OOI) from those reported for North American Blacks" and are in close agreement with earlier studies." The mean levels of methaemoglobin in G6PD deficient subjects with HbSS or HbAS are slightly increased when compared to other groups listed.
Discussion
Studies have shown that patients with shortened RBC life span due to haemolysis have a markedly decreased level of GHb. 8 Based on this we endeavoured to answer the questions regarding the effects of the interaction of G6PD deficiency upon HbSS. While PiomeIli et al? suggested that a high prevalence of G6PD deficiency in HbSS reflects a clinically beneficial effect of this interaction, Beutler et al. 4 found similar frequencies of G6PD deficiency in HbSS patients as in their HbAA and HbAS siblings. Steinberg et al.S found that the prevalence of G6PD deficiency was not significantly different in patients stratified by age groups. They therefore concluded that G6PD deficiency probably does not affect RBC survival in males with HbSS. The GHb level in G6PD deficient subjects of 6·04 ±0·8% in the present study provides clear evidence of a decreased value (P < 0'05). In our opinion, the decreased GHb level in G6PD deficient subjects not in a state of haemolytic crisis is attributable to the presence of a circulating erythrocyte population that is not as old on average as that in normal subjects. Bernini et a/. 18 had shown that the average lifetime of G6PD deficient erythrocytes is about one quarter less than normal. Our reported value shows a decreased RBC life span and is in close agreement with the value reported by Fitzgibbons et a/. 19 Statistical analysis of the present data does not show a significant difference in the level of GHb, and hence in the RBC life span, between enzyme deficient subjects with or without HbAS (P> 0,05). This agrees with an earlier study of Heller et a/. 20 who had shown that the combination of G6PD deficiency and HbAS had no adverse effect. The relatively increased level of GHb in G6PD deficient subjects with HbSS who have blood glucose levels comparable with those of sickle cell subjects with normal G6PD activity also proved to be statistically insignificant (P> 0,05). Therefore the suggestion that, on average, G6PD deficient HbSS red cells survive longer than those of HbSS subjects without G6PD deficiency is not supported by GHb levels. Alternatively, it had been suggested that G6PD deficiency leads to an elevation of the methaemoglobin level? which consequently, in the presence of an increased level ofHbF, contributes to a pool of HbS which can decrease deoxy-HbS solubility because of their extended volume effect." Our data show an increase in the methaemoglobin level in both groups of G6PD deficient subjects with HbSS or HbAS. However, this elevation in the methaemoglobin in these subjects does not appear to affect the level of G Hb and hence RBC survival. Therefore, we find little influence of G6PD deficiency upon HbSS. Specifically, there is no evidence that G6PD deficiency enhances survival; on the contrary it may intensify haemolysis under certain conditions. The benign clinical course of Saudi HbSS patients may be due to the high HbF which is found in HbSS patients both with or without G6PD defects." It therefore remains possible that HbSS patients with G6PD deficiency may be more susceptible to the development ofhaemolysis when exposed to environmental influences that provoke haemolysis in nonhaemoglobinopathic patients with G6PD deficiency.
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